New Non-Small Cell Lung Cancer Data Have Been Reported by Researchers at Fujian Medical University Union Hospital (First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a...).

Předmět:	NON-small-cell lung carcinoma BEVACIZUMAB MEDICAL research personnel UNIVERSITY hospitals KINASE inhibitors METASTATIC breast cancer BRAF genes
Zdroj:	Immunotherapy Weekly; 12/14/2023, p606-606, 1p
Abstrakt:	A new report discusses research findings on non-small cell lung cancer conducted by researchers at Fujian Medical University Union Hospital in China. The study aimed to compare the efficacy and safety of different treatment modalities for advanced EGFR-mutated non-squamous non-small-cell lung cancer. The study included 196 patients, and the results showed that first-generation EGFR-TKI plus bevacizumab plus chemotherapy was a promising strategy for treating this type of lung cancer. The study found that this treatment combination improved progression-free survival and objective response rate in patients with metastatic organs and specific genetic mutations. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu